相关实验视频

Updated: Jul 5, 2025

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

描述EGFR突变肺腺癌的分泌体

Jennifer K Luu^1,2, Fraser D Johnson^1,3, Jana Jajarmi^1,3

¹Department of Integrative Oncology, British Columbia (BC), Cancer Research Institute, Vancouver, BC, Canada.

Frontiers in oncology

|January 23, 2024

概括

研究人员在血液中发现了三种新型蛋白质生物标志物 (MDK,GDF15,SPINT2),用于早期检测EGFR突变肺腺癌. 这些生物标志物与生存率低下有关,有助于针对性查和非吸烟者的管理.

科学领域:

在瘤学瘤学.
生物标志物发现发现
蛋白质组学是指蛋白质组学.

背景情况:

肺癌是癌症死亡的主要原因,通常在晚期出现,需要早期检测方法.
非侵入性生物标志物对于识别肺腺癌至关重要,特别是在不吸烟者和EGFR突变患者中,他们不符合当前的查标准.
由于其独特的患者人口结构,EGFR驱动的肺腺癌需要特定的诊断工具.

研究的目的:

确定用于早期检测EGFR突变肺腺癌的新型非侵入性生物标志物.
为了研究肺腺癌发育期间分泌的蛋白质的变化.
在患者队列中评估已识别的生物标志物的临床实用性.

主要方法:

质谱法用于分析EGFR驱动转化的不同阶段培养的肺细胞的分泌体.
使用正交方法验证了针对恶性转变的特异性分泌蛋白质.
候选生物标志物的临床活性在肺腺癌患者队列中使用ELISA和生存分析进行了评估.

主要成果:

量化了1020种分泌的蛋白质,确定了转化阶段之间的差异性表达.
三种蛋白质生物标记候选物 (MDK,GDF15,SPINT2) 被确定并验证.
这些生物标志物的高水平与患者的生存率差相关,特别是EGFR突变肺腺癌.

结论:

在EGFR驱动的肺腺癌进展过程中分泌的蛋白质变化为瘤促进提供了洞察力.
MDK,GDF15和SPINT2显示出在这个特定的患者亚组中作为早期检测和疾病管理的生物标志物的潜力.
这些发现支持针对EGFR突变肺腺癌风险较高的个体制定有针对性的查计划.

关键词:

欧洲农业基金会 (EGFR) 是一个.早期检测早期检测肺癌是一种肺癌.一些秘密一些秘密.转化转化转化转化转化转化转化转化

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...